Study for vulvar or anal skin cancer called EMPD
Part of Cancer clinical trials.
This study is for women with a specific rare skin cancer called extramammary Paget’s disease (EMPD) in the vulvar or perianal area. The goal is to better understand the condition and test an approach for people with primary or returning (recurrent) disease in those locations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be female.
- You must be 18 years old or older.
- You have been diagnosed with extramammary Paget’s disease (EMPD) in the vulva and/or the area around the anus (perianal).
- Your EMPD must be primary (new) or recurrent (coming back).
- You must be willing and able to sign informed consent (agree to join after learning about the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a fluorescent dye called fluorescein sodium can help surgeons see the edges of extramammary Paget's disease more clearly during vulvectomy, so they can remove all the cancer while sparing as much healthy tissue as possible.
This study tests a special light treatment (photodynamic therapy) for non-invasive Paget’s disease on the vulva that has come back after surgery. It may help by treating remaining abnormal skin cells where surgery may not remove everything.
This trial tests a combination of two drugs: disitamab vedotin (which attacks cancer cells with a certain protein) and bicalutamide (which blocks male hormones that can fuel cancer growth). It is for people with Paget's disease that has spread or cannot be removed, and whose cancer cells have specific protein markers called HER2 and AR.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
This trial tests a combination of two drugs (RC48-ADC and JS001) for advanced scrotal Paget disease that has spread or cannot be removed by surgery. The goal is to see if this treatment can help shrink or control the cancer.
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
Hear when a new Paget Disease, Extramammary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.